TrialAntimicrobial agents and chemotherapy2025
Phase 1 study of the safety, tolerability, and pharmacokinetics of a synthetic macrocyclic peptide antibiotic (BRII-693) in healthy adult participants.
Michael Watkins et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.